Please check your internet connection and try again.
# Sompraz HP (Pantoprazole)
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD).
* Maintenance of healing of erosive esophagitis.
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.
## Adult Dosing
* **Healing of Erosive Esophagitis:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg orally once daily.
* **Pathological Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome):** Starting dose is typically 40 mg orally twice daily. Doses may be increased as clinically warranted. Doses up to 240 mg daily have been administered.
## Pediatric Dosing
* **GERD (Patients 5 to 16 years):** 20 mg orally once daily for up to 8 weeks. Doses of 40 mg once daily have also been used.
* **Erosive Esophagitis (Patients 5 to 16 years):** 40 mg orally once daily for up to 8 weeks.
* **Dosing in younger pediatric patients is not well established and should be individualized.**
## Dose Adjustments
No dose adjustment is generally required for patients with hepatic or renal impairment.
## Contraindications
* Known hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use may be associated with an increased risk of *Clostridium difficile*-associated diarrhea, bone fractures (hip, wrist, spine), and vitamin B12 deficiency. Hypomagnesemia can also occur.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** PPIs can decrease the absorption of drugs like ketoconazole, itraconazole, and certain antiretrovirals (e.g., atazanavir, nelfinavir).
* **Methotrexate:** PPIs may increase methotrexate levels.
* **CYP2C19 substrates:** Pantoprazole is a moderate inhibitor of CYP2C19 and may affect the metabolism of drugs like clopidogrel.
## Monitoring
* Monitor for signs and symptoms of *Clostridium difficile*-associated diarrhea.
* Consider monitoring serum magnesium levels, especially with prolonged use or concomitant use of other drugs that cause hypomagnesemia.
* Monitor for signs of bone fracture with long-term therapy.
* Assess for efficacy and potential side effects.
## Clinical Pearls
* Administer 30 to 60 minutes before a meal.
* Do not crush or chew delayed-release tablets; swallow whole.
* Long-term use should be limited to the duration of treatment for the specific indication.
* Consider potential for drug interactions, particularly with other gastric acid-lowering agents or drugs with narrow therapeutic windows.
***
**Disclaimer:** This information is intended for healthcare professionals and is not a substitute for professional medical advice. Always consult the most current prescribing information and relevant guidelines before making any treatment decisions. Drug information can change rapidly.
